{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:26:36Z","timestamp":1785381996737,"version":"3.55.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ctrv.2023.102544","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T21:49:32Z","timestamp":1679003372000},"page":"102544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective"],"prefix":"10.1016","volume":"116","author":[{"given":"Giulia","family":"Pasello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Scattolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Caumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dell'Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Scagliori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaenrica","family":"Tin\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Benati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Sepulcri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2023.102544_b0005","article-title":"Cancer statistics, 2022","author":"Siegel","year":"2022","journal-title":"CA Cancer J CLin"},{"key":"10.1016\/j.ctrv.2023.102544_b0010","unstructured":"AIOM - AIRTUM; i numeri del cancro in Italia 2021. available at: https:\/\/www.aiom.it\/wp-content\/uploads\/2021\/10\/2021_NumeriCancro_web.pdf."},{"key":"10.1016\/j.ctrv.2023.102544_b0015","unstructured":"PASSI 2020-2021. No Title. EPICENTRO ISS, available at: https:\/\/www.epicentro.iss.it\/passi\/dati\/fumo."},{"issue":"7","key":"10.1016\/j.ctrv.2023.102544_b0020","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102544_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2023.102544_b0030","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non\u2013Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102544_b0035","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2023.102544_b0040","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102544_b0045","doi-asserted-by":"crossref","first-page":"e1085","DOI":"10.1200\/OP.20.00863","article-title":"Non\u2013Small-Cell Lung Cancer: Real-World Cost Consequence Analysis","volume":"17","author":"Buja","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102544_b0050","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1148\/radiology.201.3.8939234","article-title":"Peripheral lung cancer: Screening and detection with low-dose spinal CT versus radiography","volume":"201","author":"Kaneko","year":"1996","journal-title":"Radiology"},{"issue":"9173","key":"10.1016\/j.ctrv.2023.102544_b0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(99)06093-6","article-title":"Early Lung Cancer Action Project: Overall design and findings from baseline screening","volume":"354","author":"Henschke","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102544_b0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41571-020-00432-6","article-title":"Lung cancer LDCT screening and mortality reduction \u2014 evidence, pitfalls and future perspectives","volume":"18","author":"Oudkerk","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2023.102544_b0065","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.20.02574","article-title":"Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis","volume":"39","author":"Passiglia","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102544_b0070","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement","volume":"325","author":"Krist","year":"2021","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.ctrv.2023.102544_b0075","first-page":"687","article-title":"Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening","volume":"365","author":"NLST research team","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102544_b0080","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102544_b0085","doi-asserted-by":"crossref","unstructured":"Infante M, Cavuto S, Lutman FR oman., et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. Am J Respir Crit Care Med. 2015;191(10):1166-1175. doi:10.1164\/rccm.201408-1475OC.","DOI":"10.1164\/rccm.201408-1475OC"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102544_b0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2004.06.007","article-title":"Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer","volume":"47","author":"Gohagan","year":"2005","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102544_b0095","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2007.05.009","article-title":"Baseline results of the Depiscan study: A French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR)","volume":"58","author":"Blanchon","year":"2007","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102544_b0100","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/thoraxjnl-2016-209825","article-title":"Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial","volume":"72","author":"Paci","year":"2017","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102544_b0105","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/annonc\/mdz117","article-title":"Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy","volume":"30","author":"Pastorino","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102544_b0110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1164\/rccm.201505-1040OC","article-title":"Results of the randomized danish lung cancer screening trial with focus on high-risk profiling","volume":"193","author":"Wille","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102544_b0115","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/ijc.32486","article-title":"Lung cancer mortality reduction by LDCT screening\u2014Results from the randomized German LUSI trial","volume":"146","author":"Becker","year":"2020","journal-title":"Int J Cancer"},{"issue":"40","key":"10.1016\/j.ctrv.2023.102544_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20400","article-title":"The UK lung cancer screening trial: A pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer","volume":"20","author":"Field","year":"2016","journal-title":"Health Technol Assess (Rockv)"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102544_b0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jncics\/pky042","article-title":"Lung cancer mortality in the Lung Screening Study feasibility trial","volume":"2","author":"Doroudi","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102544_b0130","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/CEJ.0b013e328351e1b6","article-title":"Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial","volume":"21","author":"Pastorino","year":"2012","journal-title":"Eur J Cancer Prev"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102544_b0135","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/j.chest.2021.06.063","article-title":"Screening for Lung Cancer: CHEST Guideline and Expert Panel Report","volume":"160","author":"Mazzone","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.ctrv.2023.102544_b0140","article-title":"Thoracic and Extra-Thoracic Incidental findings in Lung Cancer Screening: The SUMMIT study experience","author":"Janes","year":"2022","journal-title":"WCLC Congr"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102544_b0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.lungcan.2013.08.026","article-title":"Computed tomography screening for lung cancer: Results of ten years of annual screening and validation of cosmos prediction model","volume":"82","author":"Veronesi","year":"2013","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102544_b0150","first-page":"2","article-title":"Cancer incidence and mortality in China, 2015","volume":"1","author":"Zhang","year":"2021","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102544_b0155","first-page":"1","article-title":"Sex difference and smoking effect of lung cancer incidence in asian population","volume":"13","author":"Park","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102544_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40880-017-0221-8","article-title":"Mortality outcomes of low-dose computed tomography screening for lung cancer in urban China: a decision analysis and implications for practice","volume":"36","author":"Wang","year":"2017","journal-title":"Chin J Cancer"},{"issue":"117","key":"10.1016\/j.ctrv.2023.102544_b0165","first-page":"20","article-title":"Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening","volume":"2018","author":"Yang","year":"2017","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102544_b0170","doi-asserted-by":"crossref","first-page":"723","DOI":"10.21037\/tlcr-20-700","article-title":"Feasibility of implementing a national lung cancer screening program: Interim results from the Korean Lung Cancer Screening Project (K-LUCAS)","volume":"10","author":"Lee","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102544_b0175","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S2213-2600(21)00560-9","article-title":"One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102544_b0180","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.21037\/tlcr-20-985","article-title":"Implementation of lung cancer screening: what are the main issues?","volume":"10","author":"Van Der Aalst","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102544_b0185","doi-asserted-by":"crossref","first-page":"E2229741","DOI":"10.1001\/jamanetworkopen.2022.29741","article-title":"Analysis of Eligibility for Lung Cancer Screening by Race after 2021 Changes to US Preventive Services Task Force Screening Guidelines","volume":"5","author":"Pinheiro","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102544_b0190","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S1470-2045(14)70389-4","article-title":"Lung cancer probability in patients with CT-detected pulmonary nodules: A prespecified analysis of data from the NELSON trial of low-dose CT screening","volume":"15","author":"Horeweg","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102544_b0195","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-157-11-201212040-00005","article-title":"Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: A cohort study","volume":"157","author":"Veronesi","year":"2012","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102544_b0200","doi-asserted-by":"crossref","first-page":"754","DOI":"10.6004\/jnccn.2022.0036","article-title":"Lung Cancer Screening, Version 1.2022 Featured Updates to the NCCN Guidelines","volume":"20","author":"Wood","year":"2022","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ctrv.2023.102544_b0205","unstructured":"American College of Radiology: Lung-RADS v 1.1 2022. https:\/\/www.acr.org\/Clinical-Resources\/Reporting-and-Data-Systems\/Lung-Rads. Published 2022."},{"issue":"March","key":"10.1016\/j.ctrv.2023.102544_b0210","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2020.03.015","article-title":"Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy","volume":"143","author":"Veronesi","year":"2020","journal-title":"Lung Cancer"},{"issue":"170","key":"10.1016\/j.ctrv.2023.102544_b0215","first-page":"20","article-title":"Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography","volume":"2022","author":"Grover","year":"2021","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102544_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12061672","article-title":"Recommendations for implementing lung cancer screening with low-dose computed tomography in Europe","volume":"12","author":"Veronesi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102544_b0225","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-2600(21)00210-1","article-title":"The 2021 USPSTF lung cancer screening guidelines: a new frontier","volume":"9","author":"Potter","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2023.102544_b0230","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ebiom.2018.03.027","article-title":"A Validated Clinical Risk Prediction Model for Lung Cancer in Smokers of All Ages and Exposure Types: A HUNT Study","volume":"31","author":"Markaki","year":"2018","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102544_b0235","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1200\/JCO.2016.69.2467","article-title":"Lung cancer risk prediction model incorporating lung function: Development and validation in the UK biobank prospective cohort study","volume":"35","author":"Muller","year":"2017","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2023.102544_b0240","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1001\/jama.2016.6255","article-title":"Development and validation of risk models to select ever-smokers for ct lung cancer screening","volume":"315","author":"Katki","year":"2016","journal-title":"JAMA - J Am Med Assoc"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102544_b0245","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1158\/1940-6207.CAPR-11-0237","article-title":"A Risk Model for Lung Cancer Incidence","volume":"5","author":"Hoggart","year":"2015","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.ctrv.2023.102544_b0250","article-title":"A Risk Model for Prediction of Lung Cancer","volume":"715\u2013726","author":"Spitz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2023.102544_b0255","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1211776","article-title":"Selection Criteria for Lung-Cancer Screening","author":"Tammem\u00e4gi","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102544_b0260","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1470-2045(21)00590-8","article-title":"USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a prospective cohort study","volume":"23","author":"Tammem\u00e4gi","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102544_b0265","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/thoraxjnl-2020-214626","article-title":"Analysis of lung cancer risk model (PLCO M2012 and LLP v2) performance in a community-based lung cancer screening programme","volume":"75","author":"Lebrett","year":"2020","journal-title":"Thorax"},{"issue":"468","key":"10.1016\/j.ctrv.2023.102544_b0270","first-page":"82","article-title":"Epidemiology of lung cancer and lung cancer screening programs in China and the United States","volume":"2020","author":"Yang","year":"2019","journal-title":"Cancer Lett"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102544_b0275","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1470-2045(19)30329-8","article-title":"5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study","volume":"20","author":"Luo","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102544_b0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2021.11.015","article-title":"Lung Cancer A risk prediction model for selecting high-risk population for computed tomography lung cancer screening in China","volume":"163","author":"Guo","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2023.102544_b0285","article-title":"Construction and Validation of a Lung Cancer Risk Prediction Model for Non-Smokers in China. Front","volume":"11","author":"Guo","year":"2022","journal-title":"Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102544_b0290","first-page":"1","article-title":"Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins","volume":"4","author":"Guida","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2023.102544_b0295","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01460","article-title":"Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment","author":"Fahrmann","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102544_b0300","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102544_b0305","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/CMAR.S187317","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ctrv.2023.102544_b0310","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011430","article-title":"Adjuvant chemotherapy for resected early-stage non-small cell lung cancer (Review)","author":"Burdett","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102544_b0315","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194811","article-title":"Management of resectable stage III-N2 non-small-cell lung cancer (NSCLC) in the age of immunotherapy","volume":"13","author":"Mielgo-Rubio","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2023.102544_b0320","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-Mutated Non\u2013Small-Cell Lung Cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102544_b0325","article-title":"Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA","author":"Tsuboi","year":"2022","journal-title":"ESMO"},{"issue":"13","key":"10.1016\/j.ctrv.2023.102544_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137222","article-title":"Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials","volume":"23","author":"de Scordilli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2023.102544_b0335","article-title":"An open-label, prospective, phase II, umbrella study of precise neoadjuvant therapy for patients with stage II-IIIB resectable non-small cell lung cancer (PURPOSE)","author":"Wang","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102544_b0340","doi-asserted-by":"crossref","unstructured":"Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement 4):iv192-iv237. doi:10.1093\/annonc\/mdy275.","DOI":"10.1093\/annonc\/mdy275"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102544_b0345","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ctrv.2023.102544_b0350","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2023.102544_b0355","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non\u2013Small-Cell Lung Cancer","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102544_b0360","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","volume":"31","author":"Paz-Ares","year":"2020","journal-title":"Ann Oncol"},{"issue":"10308","key":"10.1016\/j.ctrv.2023.102544_b0365","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102544_b0370","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB \u2013 IIIA non-small-cell lung cancer (PEARLS \/ KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2023.102544_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1056","article-title":"PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS\/KEYNOTE-091","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102544_b0380","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer\u2014A Meta-Analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102544_b0385","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: A re-analysis of meta-analyses of individual patients\u2019 data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.ctrv.2023.102544_b0390","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1200\/JCO.2015.62.6812","article-title":"Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE)","volume":"33","author":"Eberhardt","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2023.102544_b0395","doi-asserted-by":"crossref","unstructured":"Hellmann MD, Chaft JE, Jr WNW, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers\u00a0: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42-e50. doi:10.1016\/S1470-2045(13)70334-6.","DOI":"10.1016\/S1470-2045(13)70334-6"},{"issue":"6477","key":"10.1016\/j.ctrv.2023.102544_b0400","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science (80-)"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102544_b0405","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2023.102544_b0410","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102544_b0415","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102544_b0420","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102544_b0425","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102544_b0430","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"issue":"August","key":"10.1016\/j.ctrv.2023.102544_b0435","first-page":"1","article-title":"From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1\/PD-L1 blockades","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102544_b0440","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/aje\/kwaa234","article-title":"Tracing Lung Cancer Risk Factors Through Mutational Signatures in Never-Smokers","volume":"190","author":"Landi","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"September","key":"10.1016\/j.ctrv.2023.102544_b0445","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S2213-2600(21)00164-8","article-title":"Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","author":"Ebrahimi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2023.102544_b0450","article-title":"Mechanism of Action and an Actionable Inflammatory Axis for Air Pollution Induced Non-Small Cell Lung Cancer: Towards Molecular Cancer Prevention","author":"Swanton","year":"2022","journal-title":"ESMO Congr"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102544_b0455","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jtho.2021.01.318","article-title":"National Lung Cancer Screening Program in Taiwan: The TALENT Study","volume":"16","author":"Yang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2023.102544_b0460","doi-asserted-by":"crossref","DOI":"10.3961\/jpmph.21.600","article-title":"Lung Cancer Screening With Low-dose Chest Computed Tomography: Experience From Radon-contaminated Regions in Kazakhstan","author":"Panina","year":"2022","journal-title":"J PREV Med Public Heal"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102544_b0465","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4024-3","article-title":"Serum and blood based biomarkers for lung cancer screening: A systematic review","volume":"18","author":"Chu","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2023.102544_b0470","first-page":"539","article-title":"Emerging Approches to Complement Low-Dose Computerized Tomography for Lung Cancer Screening: A Narrative Review","volume":"388","author":"Maller","year":"2022","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102544_b0475","doi-asserted-by":"crossref","DOI":"10.3390\/life11111273","article-title":"A potential serum biomarker for screening lung cancer risk in high level environmental radon areas: A pilot study","volume":"11","author":"Autsavapromporn","year":"2021","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102544_b0480","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jtho.2018.11.023","article-title":"Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges","volume":"14","author":"Seijo","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2023.102544_b0485","doi-asserted-by":"crossref","unstructured":"Zhong S, Golpon H, Zardo P, Borlak J. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl Res. 2021;230:164-196. doi:10.1016\/j.trsl.2020.11.012.","DOI":"10.1016\/j.trsl.2020.11.012"},{"issue":"11","key":"10.1016\/j.ctrv.2023.102544_b0490","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jtho.2022.07.007","article-title":"Cytisine Therapy Improved Smoking Cessation in the Randomized Screening and Multiple Intervention on Lung Epidemics Lung Cancer Screening Trial","volume":"17","author":"Pastorino","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2023.102544_b0495","doi-asserted-by":"crossref","DOI":"10.1002\/cac2.12346","article-title":"A serum microRNA signature for enhanced selection of people for lung cancer screening","author":"Yu","year":"2022","journal-title":"Cancer Commun"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102544_b0500","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.annonc.2022.01.008","article-title":"Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial","volume":"33","author":"Pastorino","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2023.102544_b0505","series-title":"Value of Computer-Aided Diagnosis (CAD) on Radiologists\u2019 Workflow and Reccomendation for Reporting Lung Cancer Screening LDCT","author":"Yuan","year":"2022"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102544_b0510","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11091610","article-title":"A low-dose CT-based radiomic model to improve characterization and screening recall intervals of indeterminate prevalent pulmonary nodules","volume":"11","author":"Rundo","year":"2021","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102544_b0515","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1164\/rccm.201507-1420OC","article-title":"The association between smoking abstinence and mortality in the national lung screening trial","volume":"193","author":"Tanner","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102544_b0520","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06568-3","article-title":"Study protocol of a multiphase optimization strategy trial (MOST) for delivery of smoking cessation treatment in lung cancer screening settings","volume":"23","author":"Ostroff","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.ctrv.2023.102544_b0525","series-title":"Lung Cancer Screening: Momentum to Quit","author":"Jassem","year":"2022"},{"issue":"May","key":"10.1016\/j.ctrv.2023.102544_b0530","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2020.05.013","article-title":"Lung Cancer Predictors of participant nonadherence in lung cancer screening programs: a systematic review and meta-analysis","volume":"146","author":"Lam","year":"2020","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2023.102544_b0535","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201905-0946OC","article-title":"Lung screen uptake trial (LSUT): Randomized controlled clinical trial testing targeted invitation materials","volume":"201","author":"Quaife","year":"2020","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722300035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030573722300035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:28:41Z","timestamp":1759656521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030573722300035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":107,"alternative-id":["S030573722300035X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102544","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102544"}}